Exploring Key Insights of the Spinal Muscular Atrophy Market: Growth Prospects, Emerging Trends, and Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Rapidly is the Spinal Muscular Atrophy Market Expected to Expand Between 2025 and 2034 Based on Current Trends?
The market size for spinal muscular atrophy has seen substantial growth in recent years. Projected to expand from $3.53 billion in 2024 to $4.01 billion in 2025, it boasts a compound annual growth rate (CAGR) of 13.5%. This significant growth in the historic period can be credited to factors such as more accurate diagnoses and early detection, rising prevalence of uncommon genetic disorders, advancements in healthcare infrastructure, government assistance and regulation, and a growth in unfulfilled healthcare necessities.
The market for spinal muscular atrophy is set to experience a significant expansion in the upcoming years, with projected growth to $6.59 billion by 2029, and a compound annual growth rate (CAGR) of 13.2%. This anticipated growth during the forecast period is attributed to numerous factors including an increase in awareness and diagnosis, improved access to treatments, heightened healthcare investments in rare diseases, supportive regulatory circumstances, and overall rise in healthcare expenditure. Key trends expected during this forecast period involve advancements in oral therapies, the incorporation of gene therapy, technological improvements in drug delivery systems, application of artificial intelligence in the development of SMA treatments, and gene editing technologies.
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Spinal Muscular Atrophy Market?
The growth of the spinal muscular atrophy market is anticipated to be bolstered by the increasing occurrence of rare genetic disorders. These disorders arise from gene mutations impacting a small population segment, typically inducing serious, enduring health issues. The escalating prevalence of these rare genetic diseases is due to enhanced diagnostic techniques, increased consciousness, and improved access to genetic testing, resulting in greater case identification and reporting. Spinal muscular atrophy (SMA) serves as a prime example of the issues and potentials in comprehending inherited diseases, emphasizing the criticality of progressing research into genetic disorders. As per a report unveiled by the Office for National Statistics, a government department in the UK, in July 2023, genetic testing of SMN1 has facilitated accurate epidemiological studies. These reveal that SMA manifests in 1 of 10,000 to 20,000 live births, and over 95% of the patients impacted are homozygous for SMN1 deletion. Hence, the increasing occurrence of rare genetic disorders will spur the growth of the spinal muscular atrophy market.
Request Your Free Spinal Muscular Atrophy Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp
Which Key Players Are Shaping the Future of the Spinal Muscular Atrophy Market?
Major companies operating in the spinal muscular atrophy market are:
• Pfizer Inc._x000D_
• F. Hoffmann-La Roche Ltd_x000D_
• Bayer AG_x000D_
• Novartis AG_x000D_
• Biogen Inc._x000D_
How Are the Latest Trends Influencing the Growth of the Spinal Muscular Atrophy Market?
In a move to enhance dosage adherence and ease consumption for pediatric patients experiencing swallowing challenges, top firms in the spinal muscular atrophy industry are pioneering the creation of innovative medicine forms like dry syrup. Using water to create a consumable medication from powder, dry syrup is typically recommended for pediatric patients who struggle with swallowing capsules or tablets. Illustratively, in September 2024, Chugai Pharmaceutical Co., Ltd., a pharmaceutical pioneer based in Japan, received an expanded indication approval from the national Ministry of Health, Labour, and Welfare for its Evrysdi (risdiplam) medication. This endorsement allows Evrysdi’s application for asymptomatic spinal muscular atrophy (SMA) and extends its usage to infants under two months. This advancement is significant as it facilitates treatment initiation before the manifestation of symptoms, potentially improving therapeutic results for affected infants. The RAINBOWFISH study, which investigated the safety and efficiency of Evrysdi in asymptomatic infants diagnosed with SMA, supported this decision. The results revealed that the infants treated achieved developmental goals such as independent sitting and enhanced motor skills by 12 months, highlighting the medication’s potential to influence the disease’s progression positively when administered early.
Pre-order Your Report for Quick and Easy Delivery!
https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report
What Are the Major Segments of the Spinal Muscular Atrophy Market and Their Role in Driving Growth?
The spinal muscular atrophy market covered in this report is segmented –
1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)
2) By Age: Pediatric, Adults
3) By Treatment: Drug Therapy, Gene Therapy
4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy
Subsegments:
1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA
2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA
3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA
4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA
What Regions Are At the Forefront of Spinal Muscular Atrophy Market Expansion?
North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can We Define the Spinal Muscular Atrophy Market and Its Key Components?
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by the progressive loss of motor neurons in the spinal cord, leading to muscle weakness and atrophy. It is caused by mutations in the SMN1 gene, resulting in insufficient survival motor neuron (SMN) protein. SMA affects voluntary muscle movements, particularly those involved in walking, swallowing, and breathing.
Browse Through More Similar Reports By The Business Research Company:
Optic Atrophy Management Global Market Report 2025
https://thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report
Spinal Surgery Devices And Equipment Global Market Report 2025
Cerebrospinal Fluid Management CSF Devices And Equipment Global Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: